Company profile: Immunomic Therapeutics
1.1 - Company Overview
Company description
- Provider of lysosomal associated membrane protein-based immunotherapies and vaccines via its UNITE platform, leveraging natural biochemistry to elicit broad immune responses. Pipeline includes ITI-1000 (autologous dendritic cell therapy for glioblastoma), ITI-1001 (off-the-shelf CMV-targeting GBM immunotherapy), ITI-3000 (plasmid DNA vaccine for Merkel cell carcinoma), ITI-1771 (for CMV-driven cancers), and ITI-5000 (saRNA vaccine for TNBC).
Products and services
- ITI-1000: Constructs an autologous dendritic cell therapy for glioblastoma, using patient-derived dendritic cells loaded with mRNA encoding the hLAMP:pp65 gene
- ITI-1001: Delivers an off-the-shelf cancer immunotherapy targeting CMV-associated antigens for newly-diagnosed glioblastoma multiforme patients, focusing on CMV-linked tumor antigens
- UNITE® Platform: Engineers a proprietary platform that harnesses the body’s natural biochemistry to develop vaccines designed to generate broad immune responses
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Immunomic Therapeutics
RITA Medical Systems
HQ: United States
Website
- Description: Provider of innovative tumor ablation products, developing, manufacturing and marketing the proprietary RITA system, which uses radiofrequency energy to heat tissue to ablate it or cause cell death, with a current focus on liver cancer and metastatic bone cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RITA Medical Systems company profile →
Cellcentric
HQ: United Kingdom
Website
- Description: Provider of clinical-stage biotechnology therapies targeting p300/CBP inhibition to treat specific cancers, particularly solid tumors; developing the oral drug Inobrodib, currently in Phase I/II trials, with potential utility in non-small cell lung, breast, colon cancers and multiple myeloma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellcentric company profile →
ScandiDos
HQ: Sweden
Website
- Description: Provider of a unique measurement system for radiation therapy in cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ScandiDos company profile →
Ariad Pharmaceuticals
HQ: United States
Website
- Description: Provider of oncology medicines, focused on the discovery, development and commercialization of treatments for cancer patients, including Iclusig for certain types of leukemia targeting cancer cells with specific genetic mutations; based in Cambridge, Massachusetts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ariad Pharmaceuticals company profile →
Eikonoklastes
HQ: United States
Website
- Description: Provider of gene therapies that increase Caveolin-1 expression in neurons to address neurodegenerative diseases, including ET-101, designed to overexpress Caveolin-1 and potentially benefit patients with ALS, Parkinson’s, Huntington’s, MS, and dementia, and SynCav1, which enhances neuroprotection and neuroplasticity for a wide range of neurodegenerative conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eikonoklastes company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Immunomic Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Immunomic Therapeutics
2.2 - Growth funds investing in similar companies to Immunomic Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Immunomic Therapeutics
4.2 - Public trading comparable groups for Immunomic Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →